




EMLc
ATC codes: [A02BA02](#)

Indication	Peptic ulcer, site unspecified <span>ICD11 code: <a href="#">DA61</a></span>
INN	Ranitidine
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Formulations	Oral > Liquid: 75 mg per 5 mL (as hydrochloride) Oral > Solid: 150 mg (as hydrochloride) Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
EML status history	First added in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations	Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)
Therapeutic alternatives limitations for EMLc	Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup A02BA H2-receptor antagonists (excluding combinations)
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Ranitidine</a> 
DrugBank	<a href="#">Ranitidine</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, A02BA H2-receptor antagonists (excluding combinations), be specified as therapeutic alternatives under the square box listing for ranitidine on the EML and EMLc.

